Sequana Medical NV (EBR:SEQUA)
Belgium
· Delayed Price · Currency is EUR 1.014
-0.012 (-1.17%)
May 14, 2025, 11:25 AM CET
Sequana Medical NV Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 0.11 | 0.71 | 0.92 | 0.37 | 0.96 | Upgrade
|
| Revenue Growth (YoY) | -85.19% | -22.81% | 149.04% | -61.54% | -0.76% | Upgrade
|
| Cost of Revenue | 0.03 | 0.16 | 0.2 | 0.08 | 0.2 | Upgrade
|
| Gross Profit | 0.08 | 0.55 | 0.72 | 0.29 | 0.76 | Upgrade
|
| Selling, General & Admin | 17.1 | 26 | 25.49 | 20.91 | 16.71 | Upgrade
|
| Research & Development | 1.68 | 4.04 | 3.85 | 3.21 | 1.86 | Upgrade
|
| Other Operating Expenses | - | - | - | - | -0.04 | Upgrade
|
| Operating Expenses | 18.79 | 30.04 | 29.34 | 24.11 | 18.53 | Upgrade
|
| Operating Income | -18.71 | -29.49 | -28.62 | -23.82 | -17.77 | Upgrade
|
| Interest Expense | -2.64 | -1.99 | -0.88 | -0.56 | -1.08 | Upgrade
|
| Interest & Investment Income | - | 0 | 0 | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -0.02 | -0 | -0.29 | -0.04 | -0.11 | Upgrade
|
| Other Non Operating Income (Expenses) | -23.01 | -0.62 | -0.58 | 1.19 | - | Upgrade
|
| EBT Excluding Unusual Items | -44.37 | -32.1 | -30.38 | -23.22 | -18.95 | Upgrade
|
| Pretax Income | -44.37 | -32.1 | -30.38 | -23.22 | -18.95 | Upgrade
|
| Income Tax Expense | 0.28 | 0.47 | 0.39 | 0.39 | 0.16 | Upgrade
|
| Net Income | -44.65 | -32.56 | -30.76 | -23.62 | -19.11 | Upgrade
|
| Net Income to Common | -44.65 | -32.56 | -30.76 | -23.62 | -19.11 | Upgrade
|
| Shares Outstanding (Basic) | 37 | 27 | 23 | 18 | 15 | Upgrade
|
| Shares Outstanding (Diluted) | 37 | 27 | 23 | 18 | 15 | Upgrade
|
| Shares Change (YoY) | 37.26% | 17.59% | 25.02% | 18.96% | 24.51% | Upgrade
|
| EPS (Basic) | -1.22 | -1.22 | -1.35 | -1.30 | -1.25 | Upgrade
|
| EPS (Diluted) | -1.22 | -1.22 | -1.35 | -1.30 | -1.25 | Upgrade
|
| Free Cash Flow | -20.35 | -29.77 | -28.16 | -23.94 | -17.14 | Upgrade
|
| Free Cash Flow Per Share | -0.55 | -1.11 | -1.24 | -1.31 | -1.12 | Upgrade
|
| Gross Margin | 74.94% | 76.95% | 77.83% | 79.31% | 78.99% | Upgrade
|
| Operating Margin | -17731.38% | -4141.06% | -3102.32% | -6428.78% | -1844.86% | Upgrade
|
| Profit Margin | -42325.70% | -4572.43% | -3334.08% | -6373.84% | -1983.45% | Upgrade
|
| Free Cash Flow Margin | -19292.21% | -4180.74% | -3051.80% | -6462.39% | -1779.67% | Upgrade
|
| EBITDA | -18.41 | -29.14 | -28.62 | -23.68 | -17.68 | Upgrade
|
| D&A For EBITDA | 0.3 | 0.35 | - | 0.14 | 0.09 | Upgrade
|
| EBIT | -18.71 | -29.49 | -28.62 | -23.82 | -17.77 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.